retatrutide phase 2 trial type 2 diabetes weight loss 2024 Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released results demonstrating 25% in half of people with #obesity. This amount of weight loss has not been accomplished Eli Lilly's Retatrutide Achieves 20%

[2] [3] For many patients with established cardiovascular disease or high cardiovascular risk, SGLT2 inhibitors are preferred before GLP-1 receptor agonists where appropriate

The good news is that you dont have to be famous or navigate confusing online programs to explore these treatments

Injectable Semaglutide and Levothyroxine While the formal pharmacokinetic study examined oral semaglutide specifically, injectable semaglutide (Ozempic, Wegovy) and tirzepatide also slow gastric emptying

This position alone can reduce straining by up to 50% according to research published in the Journal of Clinical Gastroenterology